by Andrii Buvailo, PhD
Aging is the biggest single risk factor for most chronic diseases, yet drug development still goes after them one at a time, and regulators do not treat aging itself as …
Read More
by Andrii Buvailo, PhD
Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, has raised $5 billion in a Series C round. Greenoaks and Sequoia Capital co-led the round, and Andreessen …
Read More
by BiopharmaTrend
Latest changes · November 16, 2026 First edition as a living tracker, replacing our February 2024 article. 10 companies added. Roivant Discovery is now PsiThera, an independent company with a …
Read More
by Andrii Buvailo, PhD
Paris techbio Orakl Oncology has raised a $34 million Series A co-led by Norrsken VC and Singular. InfraVia, Serena, Bpifrance’s Patient Autonome Fund, teampact.ventures and Plug and Play also joined …
Read More
by Anastasiia Rohozianska
Clinical development is still shaped by a stubborn asymmetry: only around one in ten drug candidates that enter human testing ever reaches approval, and Phase II/III failures remain the biggest …
Read More
by Andrii Buvailo, PhD
A specific idea is increasingly taking hold in 2026: that the raw material for the next generation of medicines is not more compute or cleverer algorithms, but stored human biology …
Read More